Jha Shweta, Sanyal Indraneel, Amla D V
Plant Transgenic Lab, MB and GE Division, CSIR-National Botanical Research Institute, P.O. Box 436, Rana Pratap Marg, Lucknow 226 001, India.
Biochim Biophys Acta. 2014 Jan;1840(1):416-27. doi: 10.1016/j.bbagen.2013.09.034. Epub 2013 Sep 30.
Human α1-proteinase inhibitor (α1-PI) is the most abundant serine protease inhibitor in the blood and the heterologous expression of recombinant α1-PI has great potential for possible therapeutic applications. However, stability and functional efficacy of the recombinant protein expressed in alternate hosts are of major concern.
Five variants of plant-expressed recombinant α1-PI protein were developed by incorporating single amino acid substitutions at specific sites, namely F51C, F51L, A70G, M358V and M374I. Purified recombinant α1-PI variants were analyzed for their expression, biological activity, oxidation-resistance, conformational and thermal stability by DAC-ELISA, porcine pancreatic elastase (PPE) inhibition assays, transverse urea gradient (TUG) gel electrophoresis, fluorescence spectroscopy and far-UV CD spectroscopy.
Urea-induced unfolding of recombinant α1-PI variants revealed that the F51C mutation shifted the mid-point of transition from 1.4M to 4.3M, thus increasing the conformational stability close to the human plasma form, followed by F51L, A70G and M374I variants. The variants also exhibited enhanced stability for heat denaturation, and the size-reducing substitution at Phe51 slowed down the deactivation rate ~5-fold at 54°C. The M358V mutation at the active site of the protein did not significantly affect the conformational or thermal stability of the recombinant α1-PI but provided enhanced resistance to oxidative inactivation.
Our results suggest that single amino acid substitutions resulted in improved stability and oxidation-resistance of the plant-derived recombinant α1-PI protein, without inflicting the inhibitory activity of the protein.
Our results demonstrate the significance of engineered modifications in plant-derived recombinant α1-PI protein molecule for further therapeutic development.
人α1-蛋白酶抑制剂(α1-PI)是血液中含量最丰富的丝氨酸蛋白酶抑制剂,重组α1-PI的异源表达在潜在治疗应用方面具有巨大潜力。然而,在替代宿主中表达的重组蛋白的稳定性和功能效力是主要关注点。
通过在特定位点引入单氨基酸替换,即F51C、F51L、A70G、M358V和M374I,开发了五种植物表达的重组α1-PI蛋白变体。通过DAC-ELISA、猪胰弹性蛋白酶(PPE)抑制试验、横向尿素梯度(TUG)凝胶电泳、荧光光谱和远紫外圆二色光谱,对纯化的重组α1-PI变体的表达、生物活性、抗氧化性、构象和热稳定性进行了分析。
尿素诱导的重组α1-PI变体解折叠显示,F51C突变使转变中点从1.4M移至4.3M,从而增加了接近人血浆形式的构象稳定性,其次是F51L、A70G和M374I变体。这些变体还表现出增强的热变性稳定性,苯丙氨酸51处的减小组分替换在54°C下使失活速率减慢约5倍。蛋白质活性位点的M358V突变对重组α1-PI的构象或热稳定性没有显著影响,但增强了对氧化失活的抗性。
我们的结果表明,单氨基酸替换提高了植物源重组α1-PI蛋白的稳定性和抗氧化性,而不影响该蛋白的抑制活性。
我们的结果证明了对植物源重组α1-PI蛋白分子进行工程修饰对进一步治疗开发的重要性。